UPDATE 3-Celgene 1st quarter sales miss; expects psoriasis drug rebound

April 27 (Reuters) - Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.